76 related articles for article (PubMed ID: 33291073)
21. SRSF protein kinase 1 modulates RAN translation and suppresses CGG repeat toxicity.
Malik I; Tseng YJ; Wright SE; Zheng K; Ramaiyer P; Green KM; Todd PK
EMBO Mol Med; 2021 Nov; 13(11):e14163. PubMed ID: 34542927
[TBL] [Abstract][Full Text] [Related]
22. High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer's disease using computational approaches.
Shukla R; Singh TR
J Genet Eng Biotechnol; 2021 May; 19(1):61. PubMed ID: 33945025
[TBL] [Abstract][Full Text] [Related]
23. A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
Tang J; Xie Y; Huang J; Zhang L; Jiang W; Li Z; Bian J
Bioorg Med Chem; 2022 Sep; 70():116921. PubMed ID: 35863237
[TBL] [Abstract][Full Text] [Related]
24. Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis.
Duggan WP; O'Connell E; Prehn JHM; Burke JP
Mol Cell Biochem; 2022 Oct; 477(10):2451-2467. PubMed ID: 35583632
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression.
Chandra A; Ananda H; Singh N; Qamar I
Aging (Albany NY); 2020 Dec; 13(1):163-180. PubMed ID: 33291073
[TBL] [Abstract][Full Text] [Related]
26. Identification of hot spot residues on serine-arginine protein kinase-1 by molecular dynamics simulation studies.
Chandra A; Goyal N; Qamar I; Singh N
J Biomol Struct Dyn; 2021 Mar; 39(5):1579-1587. PubMed ID: 32093544
[TBL] [Abstract][Full Text] [Related]
27. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
28. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2.
Ngo JC; Chakrabarti S; Ding JH; Velazquez-Dones A; Nolen B; Aubol BE; Adams JA; Fu XD; Ghosh G
Mol Cell; 2005 Oct; 20(1):77-89. PubMed ID: 16209947
[TBL] [Abstract][Full Text] [Related]
29. Regiospecific phosphorylation control of the SR protein ASF/SF2 by SRPK1.
Ma CT; Hagopian JC; Ghosh G; Fu XD; Adams JA
J Mol Biol; 2009 Jul; 390(4):618-34. PubMed ID: 19477182
[TBL] [Abstract][Full Text] [Related]
30. The subcellular localization of SF2/ASF is regulated by direct interaction with SR protein kinases (SRPKs).
Koizumi J; Okamoto Y; Onogi H; Mayeda A; Krainer AR; Hagiwara M
J Biol Chem; 1999 Apr; 274(16):11125-31. PubMed ID: 10196197
[TBL] [Abstract][Full Text] [Related]
31. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
32. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
33. Roles of alternative splicing in modulating transcriptional regulation.
Li J; Wang Y; Rao X; Wang Y; Feng W; Liang H; Liu Y
BMC Syst Biol; 2017 Oct; 11(Suppl 5):89. PubMed ID: 28984199
[TBL] [Abstract][Full Text] [Related]
34. SRSF1 promotes vascular smooth muscle cell proliferation through a Δ133p53/EGR1/KLF5 pathway.
Xie N; Chen M; Dai R; Zhang Y; Zhao H; Song Z; Zhang L; Li Z; Feng Y; Gao H; Wang L; Zhang T; Xiao RP; Wu J; Cao CM
Nat Commun; 2017 Aug; 8():16016. PubMed ID: 28799539
[TBL] [Abstract][Full Text] [Related]
35. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells.
Liu H; Hu X; Zhu Y; Jiang G; Chen S
Tumour Biol; 2016 Jun; 37(6):7287-93. PubMed ID: 26666824
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
